Literature DB >> 25577928

Nothing new under the sun: post-traumatic stress disorders in the ancient world.

Walid Khalid Abdul-Hamid1, Jamie Hacker Hughes.   

Abstract

Herodotus' account of the Athenian spear carrier Epizelus' psychogenic mutism following the Marathon Wars is usually cited as the first documented account of post-traumatic stress disorders in historical literature. This paper describes much earlier accounts of post combat disorders that were recorded as occurring in Mesopotamia (present day Iraq) during the Assyrian dynasty (1300-609 BC). The descriptions in this paper include many symptoms of what we would now identify in current diagnostic classification systems as post-traumatic stress disorders; including flashbacks, sleep disturbance and low mood. The Mesopotamians explain the disorder in terms of spirit affliction; the spirit of those enemies whom the patient had killed during battle causing the symptoms.

Entities:  

Mesh:

Year:  2014        PMID: 25577928     DOI: 10.1163/15733823-00196p02

Source DB:  PubMed          Journal:  Early Sci Med        ISSN: 1383-7427            Impact factor:   0.756


  5 in total

1.  PTSD Treatment for Veterans: What's Working, What's New, and What's Next.

Authors:  Miriam Reisman
Journal:  P T       Date:  2016-10

2.  A Case Study in the History of Neurology.

Authors:  Gregory S Day; David F Tang-Wai; Michel C F Shamy
Journal:  Neurohospitalist       Date:  2016-05-27

3.  PTSD and the War of Words.

Authors:  Adam M Chekroud; Hieronimus Loho; Martin Paulus; John H Krystal
Journal:  Chronic Stress (Thousand Oaks)       Date:  2018-04-16

Review 4.  Progress in Personalized Psychiatric Therapy with the Example of Using Intranasal Oxytocin in PTSD Treatment.

Authors:  Sandra Szafoni; Magdalena Piegza
Journal:  J Pers Med       Date:  2022-06-29

5.  Effects of pregabalin on neurobehavior in an adult male rat model of PTSD.

Authors:  Debra A Valdivieso; Thomas G Baughan; Ursuline M Canavati; Allison M Rey; Cristal L Trotter; Destynni R Burrell; John E Buonora; Tomás Eduardo Ceremuga
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.